Abstract HIV-1 infection can lead to neurocognitive impairment collectively known as HIV-associated neurocognitive disorders (HAND). Although combined antiretroviral treatment (cART) has significantly ameliorated HIV's morbidity and mortality, persistent neuroinflammation and neurocognitive dysfunction continue. This review focuses on the current clinical and molecular evidence of the viral and host factors that influence glutamate-mediated neurotoxicity and neuropathogenesis as an important underlying mechanism during the course of HAND development. In addition, discusses potential pharmacological strategies targeting the glutamatergic system that may help prevent and improve neurological outcomes in HIV-1-infected subjects.
Introduction
HIV-1 invades the central nervous system (CNS) very early after the initial infection and establishes an infection in nonneuronal brain cells ( Fig. 1) (Carroll-Anzinger and Al-Harthi 2006; Li et al. 2011; Schnell et al. 2011; Valcour et al. 2012) , in which infection may ultimately result in the development of HIV-associated neurocognitive disorder (HAND) Moore et al. 2011) . CNS infection is believed to originate in the peripheral trafficking of activated infected cells such as monocyte-derived macrophages (MDM) and lymphocytes, both of which reach the CNS through meningeal and parenchymal tissues (Lamers et al. 2011) . The "Trojan Horse Hypothesis" model states that, in HIV + subjects, the loss of blood-brain barrier (BBB) integrity allows infected cells to enter the CNS. HIV released from the infected cells causes infection in brain tissues resulting in inflammation, neuronal damage and the establishment of central reservoirs (Ghafouri et al. 2006; Kaul 2009; Lamers et al. 2011) .
The HIV-related neurocognitive complications comprise three conditions: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-1-associated dementia (HAD) (Antinori et al. 2007 ). In each category, the neuropathological correlate HIV-1 encephalitis (HIVE) may accompany the onset of disease ) and, in some cases, promote a worse neurological outcome. The widespread use of combined antiretroviral therapy (cART) has resulted in a higher prevalence of the milder forms of HAND (ANI, MND). The basis for the persistence of the milder forms of cognitive impairment remains unclear but suggests that HIV-associated neurodegenerative pathology persists in the brain despite cART. This means that the impact of neurologic comorbidity on HIV-1-infected individuals has become a significant clinical challenge: HIV + individuals are living longer and the mental deficits that characterize HAND often interfere with the cognitively demanding activities found in everyday life (Heaton et al. 2004; Hinkin et al. 2004 ). In addition, HAND is associated with an increased risk for early mortality independent of clinical predictors (Antinori et al. 2007; Cherner et al. 2007; Everall et al. 2009; Vivithanaporn et al. 2010) . The etiology for the development of neuropathologic manifestations in HAND include marked neuronal death, loss of synaptic plasticity, improper neurotransmitter balance and loss of metabolic functions that results from chronic pro-inflammatory states and immunologic failure (Kaul 2008 (Kaul , 2009 ). Current research indicates complex regulatory dynamics and concerted roles of the CNS glutamatergic system in neurological disorders. This has stimulated research into the molecular mechanisms underlying glutamate regulation in the neuropathogenic basis of HAND (Kaul 2009; Potter et al. 2013) . A genome-wide screening of transcriptional regulation in the brain tissue of HIV + neurocognitively impaired subjects with and without HIVE revealed that there are two patterns of differential gene expression in HAND (Gelman et al. 2012) . Gene expression in HAND subjects with HIVE is characterized by the upregulation of inflammatory genes and the downregulation of neuronal transcripts, whereas in subjects without HIVE, the pattern of gene expression is characterized by a lack of neuronally expressed changes in the neocortex and the upregulation of endothelial cell-type transcripts, suggesting that more than one pathophysiological process occurs in HAND (Gelman et al. 2012) .
The use of cART has proven to be effective in improving neurocognitive function in patients with HAND (Bogoch et al. 2011; Cysique et al. 2009 ). The cART regimen aims towards controlling systemic viremia and inflammation (Gendelman et al. 1998) , improving immunological function, and preventing extensive CNS inflammation , resulting in increased in life expectancy and decreased + T cells and MDM modulate upregulation of adhesion factors and downregulation in tight junction proteins to facilitate cellular attachment of peripherally activated or infected immune cells to endothelial cells of the blood-brain barrier (BBB). Loss of BBB integrity and increase in its permeability allow peripheral circulating CD4 + T cells and HIV-1-infected MDM to enter the brain parenchyma. Release of HIV-1 virions from peripherally infected immune cells into the extracellular CNS milieu contributes to infection of resident microglia and local astrocytes. Although, neurons are spared from direct infection by HIV-1, they are susceptible to the resulting damage via secretion of viral toxins and other neurotoxins from activated or infected MDM, microglia and astrocytes. CNS immune activation leads to release of soluble host neurotoxic mediators including pro-inflammatory cytokines, arachidonic acid, matrix metalloproteinases, glutamate and RNS/ROS which in turn lead to indirect neuronal dysfunction, dendritic loss and neuronal death. Likewise, release of viral proteins such as gp120 and Tat further enhance and sustain the inflammatory processes that potentiate and drive neuropathogenesis. Disruption in astroglial and microglial functions by inflammation-driven neurotoxicity may play a pivotal role in the pathological features that include: viral replication, altered BBB integrity, neuronal/glial dysfunction and apoptosis that ultimately ensue in HAND HIV-related neurological complications (Parsons et al. 2006) . Although cART does not completely eradicate viral-induced neurologic dysfunction, it has proven considerably effective in ameliorating further CNS progression by preventing neuronal death and decreasing CNS viral titers (Gendelman et al. 1998; Xia et al. 2011) .
While multiple mechanisms are likely at play during the development and progression of HAND, in this review we place a special emphasis on the evidence which indicates that astrocytes play a significant role in such development and progression. Astrocytes are the primary CNS cells that mediate and contribute physiologic and pathophysiologic regulation within the brain and thus represent both causative and consequential players during various neurologic disease processes. Astrocytes in HAND development and progression have been previously regarded as being secondary players of the mechanisms driving the neuropathology in HIV-1 infection. However, in this review, we will emphasize both the direct and the indirect data that highlight key aspects of astrocytes as important modulators of HIV-1 neuropathology, which data may provide novel targets and new insights for the development of adjunctive pharmacological treatment for ameliorating HAND.
HAND and inflammatory mediators
HIV-1 infection of the CNS is associated with neuroinflammation and immune activation that lead to neuronal injury. HIV + subjects with neurologic impairments display higher levels of inflammatory markers in CSF and plasma than do individuals who do not have HIV or those who are HIV + but who are without any kind of neurological burden. The proinflammatory cytokine profile in the CSF and brains of HIV + subjects with neurological impairments is characterized by elevated glutamate-responsive factors, i.e., tumor necrosis factor alpha (TNF-α) (Meeker et al. 2011) , interleukin-1 beta (IL-1β), inducible nitric oxide synthase (iNOS) (Zhao et al. 2001) , IFN-γ (Meeker et al. 2011; Shapshak et al. 2004) , and IFN-γ-inducible protein CXCL10 (formerly known as IP-10) (Peluso et al. 2013) . Changes in the levels of neuronal and inflammatory markers in the CSF of HIV + subjects have been detected within 3 months of diagnosis, indicating that neuronal inflammation and injury are early events in HIV infection (Peluso et al. 2013) . Treatment naïve HAND subjects with advanced stages of immunodeficiency exhibited high CSF concentrations of IL-6 and macrophage inflammatory protein 1β (MIP-1β) as compared to treatment naïve HIV + subjects with advanced disease but without HAND (Airoldi et al. 2012) . This pro-inflammatory profile in the CNS is not specifically targeted or improved by cART, as the viral loads in plasma and CSF were decreased after antiretroviral treatment initiation, yet the levels of the pro-inflammatory cytokines remained high even after 12 weeks on antiretroviral therapy (Airoldi et al. 2012) . The cellular sources of pro-inflammatory cytokines most likely arise from infiltrating MDM and microglia, although the persistence of the proinflammatory profile indicates that other factors may also be at play throughout the course of CNS disease (Fig. 1) . HIV + subjects with neuroinflammation (HIV encephalitis [HIVE] ) are also subject to dysregulation of gene expression patterns. In post-mortem tissues from HIVE patients, the detection of hippocampal neuroinflammation was accompanied by an increase in glial fibrillary acidic protein (GFAP) immunoreactivity (Anthony et al. 2005) , suggesting that astrocytes have an active role in the modulation of the disease. Other genes that have been found to be dysregulated include: upregulation of the signal transducer and activator of transcription gene (STAT-1), downregulation of the ionotropic glutamate receptor (NMDAR), and downregulation of the microtubule-associated protein 2 (MAP-2) neuronal marker ), some of which are known to participate in neuronal and glial glutamate metabolism. The findings of increased GFAP and decreased MAP-2 immunoreactivity ) correlated best with IFN-related genes, suggesting that interferons play an important role in the neuropathology. In other cases, subjects who displayed the classical neuropathological hallmarks of diffuse microglia activation, reactive gliosis, and white matter pallor presented a significant loss in the expression of excitatory amino acid transporter (EAAT-2) and upregulation of IL-1β and TNF-α.
Chronic immune activation and failure to control neuroinflammation promote greater CNS toxicity in HAND partially by modulating the glutamate-glutamine cycle (described below, Fig. 2 ). The pro-inflammatory cytokines TNF-α (Pascual et al. 2012; Ye et al. 2013; Zou and Crews 2005) , interleukin-1β (IL-1β), macrophage inflammatory protein 2 gamma (MIP-2γ) (Fang et al. 2012) , and interferon (both IFN-α and IFN-γ) Li et al. 2011 ) have been demonstrated to increase glutamate-induced neuronal death and potentiate astrocytic and microglial excitotoxicity. By facilitating viral replication and the expression of viral antigens within microglia and astrocytes (Carroll-Anzinger and Al-Harthi 2006), TNF-α and IL-1β both play major roles in the pathogenic and neurodegenerative processes seen in the brains of HIV-1-infected individuals (Brabers and Nottet 2006; Tornatore et al. 1991) . Post-mortem brains with HIVE present elevated levels of TNF-α, IFN-α, IFN-γ, and IL-1β in the prefrontal cortices, which levels may render greater permissiveness for the productive infection of astrocytes seen in the most severe case of encephalitis (Anthony et al. 2005; Masliah et al. 2004; Xing et al. 2009 ).
Additional investigation to uncover the broad repertoire of neurotoxic factors released by IFN-γ-stimulated human astrocytes revealed that glutamate neurotoxicity may act through the IFNγR-STAT3 pathway (Hashioka et al. 2011) . Human astrocytes stimulated with IFN-γ generate and release neurotoxic factors similar to reactive microglia, including arachidonic acid, glutamate, and ROS. Thus activated astrocytes may act to amplify and potentiate the neurotoxic effects exerted by activated microglia . Furthermore, neonatal murine astrocytes stimulated with TNF-α for 24 h overexpressed MIP-2γ, resulting in the downregulation of EAAT-2 (orthologous with rodent glutamate transporter, GLT-1) mRNA and protein levels. MIP-2γ was not directly toxic to neurons in culture, but rather the accompanying decrease of GLT-1 and its activity resulted in a loss of neuroprotection from high extracellular glutamate (Fang et al. 2012 ). Interferon-γ-inducible peptide-10 (CXCL10) is another neurotoxic chemokine that is elevated in during HIV infection across a broad range of clinical presentations (Asensio et al. 2001; Cinque et al. 2005) . Human astrocytes either infected with HIV-1 BaL or NL4.3 isolates or exposed to TNF-α or IFN-γ upregulate CXCL10 mRNA and protein levels. The combination of these proinflammatory cytokines (TNF-α/IFN-γ) and HIV infection further promotes CXCL10 production and enhances glutamate release in cultured human astrocytes via pro-apoptotic and inflammatory pathways involving signaling by JAK, STATs, MAPK, and NF-κB ). These results indicate that cytokines are primarily involved in regulating CNS inflammatory processes and neuronal toxicity by directly affecting the protection to neurons provided by astrocytes.
Glutamate release is subject to calcium regulation, and CD38 is an enzyme in astrocytes involved in intracellular calcium signaling. CD38 upregulation was demonstrated by immunohistochemical analysis in brain tissue from HIVE patients (Kou et al. 2009 ). Activated astrocytes increase CD38 expression after IL-1β treatment, and this upregulation is mediated by the MAPK and NF-κB signaling cascades (Mamik et al. 2011) . Thus the resulting overexpression of CD38 partially occurred because of the evoked glutamate release, which was in turn caused by elevated Ca 2+ influx (Bruzzone et al. 2004) . Further dissections of Ca 2+ -dependent signaling mechanisms have revealed a role for CXCR4 axismediated glutamate neurotoxicity as an important modulator between glia-glia and glia-neuron communication system. The stimulation of GFAP + astrocytes expressing CXCR4 with the CXCR4 natural ligand, CXCL12, required the presence of TNF-α to evoke glutamate release. Pharmacological blockage with the non-competitive CXCR4 inhibitor, AMD3100, abrogated the CXCR4 signaling pathways, preventing glutamate release (Bezzi et al. 2001) . Summed together, the resulting astrocyte dysfunction enhances glutamate-related damage as a result of the persistent and unresolved local CNS inflammatory processes that occurs in patients with HAND, especially in those subjects with HIVE.
The dysregulation of gene expression patterns is affected not only by the neuroinflammation process itself but agedependent factors may also be at play. Immunohistochemical analyses from 83 HIV + individuals to examine the differences between young versus aged subjects showed a marked GFAP and Iba-1 increase while MAP-2 was decreased in brain tissue from aged HIV + subjects with HIVE as compared to young HIV + subjects with HIVE (Fields et al. 2013 ). However, both aged and young HIV subjects with HIVE exhibited increased GFAP and Iba-1 immunostaining and decreased MAP-2 as compared to subjects without HIVE. In addition, there were also differences in the levels of autophagy related proteins in brain tissues samples from young and aged HIVE subjects (Fields et al. 2013) . As HIV becomes a more manageable chronic disease, the list of co-morbidities increases and points to the importance of characterizing the differences in brainrelated functions among young and aged HIV + individuals.
The glutamate-glutamine cycle and HAND
In the CNS, the amino acid glutamate is the major excitatory neurotransmitter and its release mediates Ca
2+
-dependent signaling events through the binding and activation of ionotropic N-methyl-D-aspartate receptors (NMDA) (Fu et al. 2013; Malarkey and Parpura 2008) . Under physiological conditions, neurons are incapable of producing glutamate de novo and thus receive glutamine as the non-toxic precursor for synthesizing glutamate, which is required for post-synaptic excitatory neurotransmission (Hertz 2011; Pardo et al. 2011 ). Neuronal glutamate is produced from glutamine by the catalytic activity of mitochondrial-bound glutaminase type 1 (GLS1) (Holcomb et al. 2000; Ye et al. 2013 ). The extracellular release of glutamate exerts its excitatory activity upon Ca 2+ -mediated activation of NMDA receptors embedded within the synaptic dendrites of glutamatergic neurons (Fu et al. 2013; Tavares et al. 2002) . The removal of extracellular glutamate from the post-synaptic cleft (Fig. 3 ) occurs via reuptake through the high-affinity Na + -dependent excitatory amino acid transporters 1 and 2 (EAAT-1 and EAAT-2), which are expressed at the plasma membrane surface of astrocytes and microglia (Lehmann et al. 2009; Qian et al. 2011) . Fig. 2 Neuron-glia interaction and the glutamate-glutamine cycle in the context of HIV infection in the CNS. Intracellular glutamate is converted to glutamine in astrocytes and is exported to the extracellular space. Glutamine enters glutamatergic neurons as a precursor for the generation of the neuronal glutamate pool, by intracellular neuronal glutaminase (GLS). Glutamate is then released into the post-synaptic cleft. Extracellular glutamate secreted from neurons and/or glia activates NMDA receptors and increase intracellular Ca 2+ levels to evoke excitatory functions (EPSP). Glutamate transporters (EAAT-1 and EAAT-2) found in the plasma membranes of glial cells mobilize excess glutamate from the extracellular space into the cell interior. Glutamate may be then metabolically fated for either glutathione synthesis (GSH) for antioxidant function, or deaminated to produce the tricarboxylic acid cycle intermediate: α-ketoglutarate. In the astrocyte, glutamate can be converted to glutamine by the action of the enzyme glutamine synthetase (GS). Several cellular-and viral-derived soluble factors modulate the glutamate-glutamine balance by altering protein expression patterns, catalytic enzyme activity, and transcriptional and translational regulation in astrocytes, microglia and neurons. HIV-1 infection in monocyte-derived macrophages (MDM), microglia and astrocytes increases production and secretion of pro-inflammatory mediators: TNF-α, IL-1β, IFN-α, and IFN-γ. HIV-1 viral proteins gp120 and Tat are secreted and further evoke the upregulation of inflammatory cytokines, the generation of reactive oxygen/nitrogen species (ROS/ RNS), and the activation of transcription and signaling factors NF-κB, JNK/STAT-1, ERK1/2, and PI3 to promote neurotoxicity. TNF-α promotes Ca 2+ -mediated caspase-dependent apoptosis via NF-κB activation and phosphorylation of STAT-1 which subsequently leads to nuclear translocation and transcription. Tat and gp120 promote STAT-1 phosphorylation. HIV-1 infection, gp120, TNF-α, and MIP-2γ downregulate EAAT-2 expression and activity and prevent excess glutamate removal. IFN-α and HIV-1 infection in MDM and microglia promote release of mitochondrial-bound GLS into the cytosol and extracellular space where it can further catalyze glutamine to generate elevated levels of glutamate. Stimulation of iNOS by either, TNF-α, HIV-1 infection or gp120 and generation of high nitric oxide levels (ONOO − ) diminishes GS expression and activity thus preventing conversion of glutamate to non-toxic glutamine. Furthermore, involvement of the CXCR4 axis in the neuropathology of HIV-1, triggered by SDF-1 or gp120 binding may further potentiate glutamate-evoked toxicity via ERK1/2 signaling pathway. Failure of these mechanisms leads to sustained neuronal NMDAR activation, Ca 2+ -mediated signaling and ultimately inflammation and cell death Thereafter, glutamate may either be amidated by the catalytic action of glutamine synthetase (GS) to replenish the intracellular pools of glutamine (Fernandes et al. 2010) or deamidated by glutamate dehydrogenase (GDH) to produce α-ketoglutarate and other amino acid intermediates for the oxidative pathway of energy production (Dadsetan et al. 2011; Skytt et al. 2012) . A summary of the genes and proteins involved in the glutamate-glutamine cycle is provided in Table 1 .
Glutamate transmission and metabolism are affected in many neurological diseases, including Alzheimer's disease (Ferrarese et al. 2001 ), Parkinson's disease (Plaitakis et al. 2010) , amyotrophic lateral sclerosis, epilepsy (Eid et al. 2013a,b) , and HIV-1-associated neurocognitive disorders (Cohen et al. 2010; Gongvatana et al. 2013; Lentz et al. 2009 ). Whether glutamate levels in CSF or plasma represents a useful indicator of HIV-associated excitotoxicity remains unclear. Initial studies to examine the potential role of glutamate in chronic neurodegenerative syndromes as a result of a retroviral infection were conducted in the LP-BM5 leukemia retrovirus mixture mouse model (Espey et al. 1998 ). The LP-BM5 infected mice develop an immunodeficiency syndrome similar to human AIDS (Kustova et al. 1997 ) and glutamate concentrations in the CSF of LP-BM5 infected mice were found to be elevated (Espey et al. 1998 ). However, analysis of human CSF revealed no correlation between the concentration of glutamate and either HIV-1 infection or HAD (Espey et al. 1999) . To the contrary, other studies found increased glutamate levels both in the CSF and plasma of HIV-infected patients and the glutamate levels positively correlated with the degree of dementia and brain atrophy (Ferrarese et al. 1997 (Ferrarese et al. , 2001 . The difference in the results was later addressed by both groups and it was recognized that the discrepancy could be due to methodological differences (Espey et al. 2002) . Nonetheless, it is widely accepted that brain metabolite dysregulation occurs early in HIV infection ) and persists in the setting of chronic and stable disease (Harezlak et al. 2011) . Clinical studies using magnetic resonance spectroscopy (MRS) to evaluate metabolite levels in early versus chronic cognitively normal HIV + subjects showed a marked reduction in the glutamate levels of HIV + subjects as compared to control Sailasuta and Ross 2009) . These studies suggest that HIV causes neuronal dysfunction soon after infection and may represent a key target for early intervention to reduce neurocognitive impairments among HIV + patients. The underlying mechanism that leads to neuropathology is somewhat unclear but it is likely to include the peripheral infiltration of HIV-1-infected MDM and subsequent infection of astrocytes and resident microglia. An examination of brain tissue samples from 589 HIV + subjects revealed that approximately 17% of the cases exhibited parenchymal brain pathology characterized by HIVE, leukoencephalopathy and microglial nodular encephalitis (Everall et al. 2009 ). Astroglial alterations have been observed in in vitro and in vivo using animal models and postmortem tissue from human AIDS patients (Persidsky et al. 2001; Wyss-Coray et al. 1996) . The localization of astrocytic HIV-1 infection in Fig. 3 Neurotransmitter uptake by glial cells (astrocytes, microglia or activated macrophages) is mediated by specific transporters located on the glial cell membrane. In the glial cell glutamate-glutamine cycle, the excess glutamate (Glu) released at the pre-synaptic cleft is transported into the glial cell by the excitatory amino acid transporters 1 and 2 (EAAT 1/2). Glutamate is converted to glutamine by glutamine synthetase (GS). Glutamine (Gln) is then transported into the extracellular space by Nsystem amino acid transporter (SNAT1) and is taken up by the neuronal SNAT. Glutamate in the neuron is generated by the action of the enzyme glutaminase (GLS) in the mitochondrial matrix. Glutamate is then loaded into synaptic vesicles with the transporter protein, vGLUT1, and then is released into the synaptic cleft. Not depicted in this pathway are: the uptake of Glu by EAAT3 or metabotropic Glu receptors (mGluRs) in the post-synaptic neuron and the action of glutamate dehydrogenase in glial cells that links glutamate metabolism with the Krebs cycle by catalyzing the reversible reaction α-ketoglutarate + NH 3 + NADH ↔ Glu + NAD + (Bezzi et al. 2001; Brabers and Nottet 2006; Xing et al. 2009 ). Astrocytes, on the other hand, comprise the major cell type population within white and grey matters and perform an array of specialized functions providing anatomical networks and physiological support to regional neurons (Zou et al. 2010) . Astrocytes are responsible for the metabolic processing of the amino acids and carbohydrates that are necessary to maintain the balance of antioxidants (Almeida et al. 2002; Lee et al. 2010a) , the generation of energy supply (Kreft et al. 2012) , the intercellular exchange of metabolic precursors (Hertz 2011; Maciejewski and Rothman 2008; Pardo et al. 2011) , and regulate neuroinflammatory responses Xu et al. 2009 ). Although some of the complex regulatory mechanisms employed by astrocytes and microglia to maintain glutamate homeostasis have yet to be dissected, HIV-1 cell culture and animal models have granted a better understanding about the contributing roles of glutamate metabolism and altered glutamate neurotransmission during the course of HIV neuropathology. In vitro studies dissecting the underlying mechanisms of astrocytic toxicity have uncovered that, despite the low percentage, infected cells astrocytes produce toxicity that promotes apoptosis in uninfected, neighboring astrocytes. The apoptotic signal transits via gap junctions to the uninfected cells (Eugenin and Berman 2007) . This novel mechanism of bystander toxicity coordinated by gap junctions has been demonstrated also in vivo using an animal model of accelerated NeuroAIDS, SIV-infected macaques (Eugenin et al. 2011) . These data indicate that a few infected astrocytes are capable of triggering bystander cell dysfunction, endothelial apoptosis and BBB compromise.
Neurons, while not directly infected by HIV-1, are susceptible to the indirect neurotoxic damage induced by cytokinestimulated or HIV-infected nearby cells (Kovalevich and Langford 2012) . For example, the microglial release of TNF-α induces the downregulation of astrocytic EAAT-2 (Tilleux et al. 2009 ) and potentiates glutamate exocytosis via mechanisms involving oxidative damage and the nuclear translocation of NF-κB (Zou and Crews 2005) . Activated microglial cells trigger the astrocytic release of glutamate to modulate excitatory transmission (Pascual et al. 2012; Patton et al. 2000) and also to decrease glutamate uptake (Takaki et al. 2012) . Experimental data from a mixed culture of astrocytes, microglia, and neurons demonstrated that the microglial response to inflammation resulted in a significant release of L-glutamate. This led to a rise in intracellular glutamate in astrocytes and a downregulation of the glutamate aspartate transporter (GLAST/EAAT-1) expression and function, which further increased extracellular glutamate concentration (Takaki et al. 2012 ). The prevention of glutamate release from microglia by carbenoxolone abrogated the response in astrocytes, indicating that under conditions of neuroinflammation, the interplay between microglia and astrocytes contributes to the disruption of the extracellular glutamate homeostasis (Takaki et al. 2012) . Interestingly, previous studies aimed at unraveling the mechanisms of EAAT-1 regulation in human astrocytes have demonstrated that TNF-α diminishes EAAT-1 promoter activity after 24 h of treatment (Kim et al. 2003) , thus suggesting that the loss of EAAT-1 may accompany the early stages of neuroinflammation in vivo. In sum, these observations indicate that the inflammatory-driven environment seen in HAND patients plays a major role in the glutamate-glutamine cycle regulation, and thus glial-neuronal communication is sensitive to the presence of inflammatory mediators.
Proton magnetic resonance spectroscopy ( 1 H MRS) has been used to monitor in vivo and ex vivo changes in brain metabolites. Several groups that use the non-human primate model of HIV/AIDS have applied 1 H MRS to evaluate brain metabolite changes associated with SIV infection and their studies have revealed metabolic abnormalities similar to those observed in HIV-infected human brains (Bossuet et al. 2004; Cloak et al. 2011; Greco et al. 2004; Kim et al. 2005; Lentz et al. 2008; Ratai et al. 2009 ). Cynomologus macaques that remain asymptomatic after infection with a pathogenic SIVmac251 isolate, demonstrate elevated glutamate levels in their prefrontal cortices and caudate putamen even with minimal CSF viral burden (Bossuet et al. 2004 ). These regions are responsible for executive functions, decision-making, social behavior, motor movements, learning, and memory. One third of the infected animals in that study, which focused on infected animals without progression, had detectable astrogliosis and microglial inflammation shown by increased GFAP and CD68 immunoreactivity by the first year of infection, even without apparent major neurologic complications. This gliosis eventually came to affect 50% of the chronically infected macaques (ranging from 24 to 83 months). The data suggest that even in individuals with asymptomatic disease, neurological inflammation and reactive gliosis in the putamen and prefrontal cortex may result in excess glutamate levels in those brain regions (Bossuet et al. 2004) . Changes in brain metabolites have been detected shortly after infection and correlate with profound astrogliosis as well as viremia (Greco et al. 2004; Kim et al. 2005) . To explore the changes in the environment of the glutamatergic synapses, the expression of the EAATs in the putamen of macaques infected with either neurotropic SIVmac251 or SIVmac239 was analyzed (Meisner et al. 2008) . Macaques that progressed to AIDS exhibited a greater loss in EAAT-1 and EAAT-2 expression as compared to asymptomatic and control macaques (Meisner et al. 2008 ). This progressive loss of EAAT-1 and EAAT-2 was associated with increased microglial activation and subsequent alteration of astrocytic function (Meisner et al. 2008) . Astrocytes are the main cell type expressing these two transporters, thus under conditions that alter the expression of the transporters (i.e., inflammation) astrocytes cease their neuroprotective activities and contribute to glutamate-mediated injury.
In addition to the improper removal of glutamate from the extracellular space and the decreased intracellular turnover to glutamine during inflammatory responses, excessive neuronal and glial production of glutamate may be an important mechanism in glutamate-evoked toxicity (Ye et al. 2013) . The upregulation and secretion of mitochondrial-bound GLS1 has been demonstrated to occur using HIV-1 infection models of both primary human microglia and MDM (Erdmann et al. 2006 (Erdmann et al. , 2009 Huang et al. 2011; Pais et al. 2008; Tian et al. 2008; Zhao et al. 2004 , Zhao et al. 2012 . The contribution of MDM-associated neurodegeneration in encephalitis became apparent when SCID HIVE mice exhibited behavioral and memory deficits during the Morris Water Maze test (ZZink et al. 2002) . These deficits, were attributed both to the loss of hippocampal expression of neuronal markers (synaptophysin, MAP-2) and to the inflammatory processes mediated by the presence of infected MDM (Anderson et al. 2003; Zink et al. 2002) . The in vivo contribution of viral infection to glutamate production has been studied by the intracranial injection of human MDM infected with HIV-1 ADA into a severe combined immunodeficiency mouse model of HIV-1 encephalitis (SCID HIVE) (Ye et al. 2013) . Notably, astrogliosis and inflammatory cytokines are evident after MDM inoculation (Persidsky et al. 1996) . Moderate HIV-1 infection within human MDM significantly increased the expression of GLS1 in neurons and led to increased glutamate production in areas of neuroinflammation, suggesting a role for glutaminase in tissue pathology (Ye et al. 2013) . The upregulation of glutaminase gene expression is mediated by the phosphorylation of STAT1 and its subsequent binding to the glutaminase promoter (Zhao et al. 2012) . The relevance of this observation has been corroborated in post-mortem brain tissues (Ye et al. 2013) as well as by HIVE subjects from the NNTC cohort who had significant increases in STAT-1 and IFN-γ mRNA levels, which occurred in parallel with a loss of glutamate receptor signaling (Gelman et al. 2012) . In addition to the modulating effects of HIV-1 infection or viral gene products on glutamate homeostasis, glutamate itself can decrease EAAT-1 and EAAT-2 expression when elevated in the extracellular space, promoting its own neurotoxic build-up in a manner that is independent of mGluR activation (Lehmann et al. 2009 ). These observations suggest that not only may viral proteins act to release excitotoxic levels of glutamate and to diminish reuptake capacity by glial cells and neurons, but also that the extracellular accumulation of glutamate due to failure in its removal can help sustain further neuronal injury.
HIV gp120 impairs the glutamate-glutamine cycle
HAND is thought to result from the complex interaction of both viral and host factors including direct and indirect mechanisms of neurotoxicity. One of the viral neurotoxins implicated as an important factor driving the neuropathogenesis of HAND is the HIV-1 envelope glycoprotein gp120. Besides its well-known role in cellular binding via the CD4 receptor and coreceptors CXCR4 and CCR5, gp120 also promotes an array of detrimental alterations that may lead to the neurodegenerative processes observed in HAND. Gp120 mediates neurotoxicity via multiple pathways leading to cellular death and the release of soluble excitotoxic mediators. There is both in vitro and in vivo evidence of gp120's ability to cause neurotoxicity. Increased immunoreactivity to GFAP and protein kinase C (PKC) occurs in gp120-treated astrocytes, in brains of gp-120 transgenic mice, and in brains from humans with HIVE (Wyss-Coray et al. 1996) . Early in vitro experiments showed that astrocytic expression of the EAAT-2 glutamate transporter was reduced rapidly upon exposure to gp120. This loss was accompanied by a reduction in glutamate uptake activity (Patton et al. 2000; Vesce et al. 1997; Wang et al. 2003 . Even though it is widely accepted that gp120 triggers neurotoxicity by directly affecting both glutamate uptake and release, the effect of gp120 in modulating CNS glutamate metabolism particularly in astrocytes continues to be an important area of research.
Increased oxidative stress is also suggested to play an important role in the neuropathogenesis of HAND (Nath 2002; Turchan et al. 2003) as glutamate toxicity may result from glutathione depletion and oxidative stress (reviewed by Gras et al. 2006) . HIV-1 gp120 impairs the endogenous cellular antioxidant defense and increases reactive oxygen species (ROS) formation (Reddy et al. 2012) . For instance, gp120 reduced the concentration of extracellular glutamine as well as the expression of GS, and these effects were accompanied by overproduction of free radicals and lipid peroxidation (Visalli et al. 2007 ). The downregulation of GS could be prevented by the antioxidant N-acetylcysteine (NAC) suggesting that an oxidative environment was the contributing factor. The antidepressant tianeptine, that interferes with the effects on glutamatergic transmission (Piroli et al. 2013; Reagan et al. 2004; Svenningsson et al. 2007 ) and decreases the production of inflammatory cytokines (Castanon et al. 2004; Mutlu et al. 2012) , increased cell viability and prevented the loss of astrocytic GS levels caused by gp120. Further examination of the mechanism of protection of tianeptine revealed that it prevented the activation of NF-κB by controlling the levels of IκB-α and thus in turn modulating the expression of iNOS and the stabilization of constitutive nitric oxide synthase (cNOS) (Janda et al. 2011) . Collectively, these data demonstrate that HIV-mediated glutamate toxicity results from the combination of persistent inflammatory stimuli, unresolved oxidative damage, and direct damage by viral proteins (i.e., gp120). Although in all likelihood this appears to be the case, whether additional mechanisms that lead to neurotoxicity are at play remains to be elucidated. Understanding the relationships between neuroinflammation, neurotoxicity and HAND disease progression is critical to elucidate the underlying mechanism and to the development of therapeutic modalities for the treatment of HAND.
Amelioration of virally induced glutamate excitotoxicity as a therapeutic approach
Although cART has successfully eradicated the most severe forms of HAND through the beneficial properties of reducing viral replication and the associated inflammatory responses (Anthony et al. 2005; Gendelman et al. 1998) , additional therapeutic modalities directed at glutamate transmission and metabolism during HIV-1 infection are highly desired to alleviate glutamate-related toxicity in the CNS (Ferrarese et al. 2001; Sailasuta and Ross 2009) . The prevention and rapid resolution of the residual inflammatory responses seen in HAND and HIVE is a major goal in mitigating the neurocognitive deficits in HIV + subjects (Meeker et al. 2011; Peluso et al. 2013; Sailasuta et al. 2012) , and, therefore, the use of anti-inflammatory drugs to reduce the neuroinflammatory effects caused by glial cells ) may, at this point, be the most straightforward pharmacological regimen available for use during HIV-1 CNS infection.
The search for anti-inflammatory agents able to act within the CNS for use during HAND and HIVE has uncovered the effectiveness of two compounds as inhibitors of proinflammatory cytokine production: BB-882, an inhibitor of platelet-activating factor, and BB-1101, an inhibitor of both matrix metalloproteinase (MMP) and TNF-α release. In the SCID HIVE mouse model, the extent of widespread astrogliosis and microglia-associated inflammation is significantly reduced with the combined use of the antiinflammatory drugs BB-882 and BB-1101 (Persidsky et al. 2001) . Moreover, these anti-inflammatory agents reduce TNF-α expression in brain tissues and are thought to prevent further neuropathology by overcoming the inhibition of glutamate reuptake (Carmen et al. 2009; Persidsky et al. 2001) . In terms of HIVE, anti-inflammatory agents that can successfully cross the BBB and neutralizing antibodies against proinflammatory cytokines may be useful tools for preventing the peripheral infiltration of HIV-1-infected CD4 + cells. Not only did the use of antibodies against IFN-α improve the pathological markers of astrogliosis and microgliosis but also the resulting neutralization was reflected in improved learning and working memory in the SCID HIVE mouse model (Sas et al. 2009 ). Whether the use of anti-inflammatory agents in combination with cART proves to be an important adjunctive therapy for diminishing glial-mediated inflammatory processes in HIVE and HAND in humans remains to be elucidated.
Another pathological mechanism in HIV-1-induced neuronal damage involves NMDAR activation (Kaul 2008) . In vitro studies have revealed that conditioned medium from HIV ADAinfected or LPS-activated MDM damages primary cortical neurons because of the elevation of glutamate levels (Jiang et al. 2001) . Extracellular glutamate binds to and stimulates ionotropic NMDAR to increase Ca 2+ influx, which causes activation of calcium/calmodulin-dependent protein kinase (CaMKII) (Mayadevi et al. 2012) and subsequently leads to membrane depolarization and postsynaptic excitatory mechanisms. The neurotoxicity caused by glutamate ensues when the overstimulation of NMDARs is accompanied with a high enough elevation of intracellular Ca 2+ levels that results in Ca 2+ -dependent mechanisms for cellular apoptosis (Lee et al. 2010b) . Interestingly, an increase in neuronal susceptibility to soluble neurotoxins from HIV-infected MDM supernatant correlates the increased expression of the NR2A and NR2B subunits (O'Donnell et al. 2006) , thus not only evidencing that the activation of NMDARs plays a central role in neuronal apoptosis during HIV-1 CNS infection but also that the protein expression patterns of the NMDAR subunits may determine the magnitude of neuronal death triggered by glutamate.
Pharmacological antagonists of the NMDAR such as dizocilpine (MK801) and amino-5-phosphonovaleric acid (AP-5) provide neuroprotective support against neuronal apoptosis after treatment with conditioned media from HIV-1-infected MDM (Chen et al. 2002) . Besides the noncompetitive blockage of glutamate stimulation on astrocytic or neuronal NMDRs (Lee et al. 2010b) , MK801 has been shown to mediate some of its protection in vitro through various mechanisms of action, including the prevention of NR2B subunit cleavage (O'Donnell et al. 2006) , inhibition of synaptosomal glutamate release (Tavares et al. 2002) , and inhibition of NMDAR-activated Ca 2+ influx (Lee et al. 2010b ) after stimulation with quinolinic acid. In addition, MK801 prevented the loss of dendritic length in neuronal cultures after the addition of increasing doses of IFN-α (Sas et al. 2009 ). Therefore, future clinical and pharmacological studies should consider and evaluate the use of MK801 as powerful and promising tool against the pathological processes in HAND and HIVE. AP-5 also inhibits NDMARs, and its effects are similar to those of the MK801. However, its use has not been studied in vivo and yet remains to be evaluated as a candidate drug for HIV-1 treatment. On the other hand, memantine, an NMDAR antagonist, has a slightly different mechanism of action (Parsons et al. 2007 ) than does MK801. In animal studies, memantine has been shown to protect from the neurotoxic effects of HIV-1 ADA -infected MDM when injected into the caudate and putamen regions of the SCID HIVE mouse model (Anderson et al. 2004 ). Measurements of synaptic transmission and synaptic plasticity in SCID HIVE mice indicated that those receiving memantine exhibit improvements in synaptic function (Anderson et al. 2004 ). Memantine has also been used in clinical trials and was determined to be safe and well tolerated by HIV-infected subjects with cognitive impairment in a phase II 20-week study (Schifitto et al. 2007 ) as well as in the 48-week extension study (Zhao et al. 2010) . Although no significant differences were observed in cognitive performance during the 20-week study, the MRS analyses suggest that memantine may ameliorate neuronal metabolism and thus may help stabilize or prevent neuronal injury (Schifitto et al. 2007 ). However, the 48-week extension study was inconclusive due to inherent study limitations and thus the question remains in terms of the efficacy of memantine for the treatment of HIV-associated cognitive impairment (Zhao et al. 2010 ). These results highlight the need for longer studies to evaluate the full potential of neuroprotective agents.
Curcumin and chemically related curcuminoids are derived from the turmeric root and have various cytoprotective attributes, including protective glutamate excitotoxicity (Wang et al. 2008) , antioxidant capacity, anti-inflammatory properties, and anti-apoptotic functions (Khanna et al. 2009 ). Some mechanisms whereby curcumin exerts its neuroprotective effects occur through the reduction of ROS within the hippocampus (Tang et al. 2009 ) and the reduction of Ca 2+ -dependent and -independent activities of CaMKII (Mayadevi et al. 2012) , which enzyme activity constitutes a downstream signaling component after the glutamate-NMDA stimulatory response. Curcumin has been shown to protect cortical neurons from caspase-3-dependent apoptosis when the cells are exposed to conditioned media from microglia stimulated with gp120 variable region 3 peptide (gp120 V3) (Guo et al. 2013) . Moreover, curcumin diminishes neurotoxic effects by reducing microglial ROS formation, decreasing TNF-α secretion, and decreasing MCP-1 production, which in turn prevents neuronal apoptosis. Rats intracranially injected with gp120 V3 and that received curcumin were more successful in completing the Morris Water Maze than the gp120 V3 group without curcumin (Tang et al. 2009 ). Hippocampal histological and electrophysiological findings respectively showed the conserved anatomical integrity of the CA1 and CA3 subregions and an increase in the magnitude of LTP in curcumintreated rats (Tang et al. 2009 ). Together, these findings provide support for the search of pharmacological modulation directed towards the glutamate-NMDAR axis to help modulate neuronal dysfunction and loss, as well as some of the HIV-1-related neurocognitive dysfunctions.
According to various groups, blocking the enzymatic activity of glutaminase (Erdmann et al. 2006 (Erdmann et al. , 2009 Ye et al. 2013; Zhao et al. 2004 , Zhao et al. 2012 or promoting the conversion of glutamate to glutamine via GS (Janda et al. 2011; Kleinkauf-Rocha et al. 2013; Muscoli et al. 2005; Visalli et al. 2007 ) may be an alternative strategy in preventing HIV-1 neuropathology. ROS and RNS are known to influence glutamate handling, as antioxidant compounds are able to restore glutamatergic homeostasis that may result from viral replication or protein-mediated oxidative effects on CNS cultures and murine models of HIV-1. Therefore, the modulation of oxidative stress may be beneficial in ameliorating neurological diseases. Pharmacological tools with mechanisms of actions that involve increased antioxidant functions have been shown to lessen the neurotoxic effects of HIV-1 infection or viral products. For example, the use of the powerful antioxidant NAC rescues the astrocytic loss of GS activity and reduces glutamate content in cell cultures when exposed to μmolar doses of recombinant HIV-1 gp120 (Visalli et al. 2007) . Despite the need to unravel molecular mechanisms whereby the antioxidant/oxidant balance correlates with glutamate dysregulation, in a similar fashion that involves overcoming oxidative stress levels, the clinically approved antidepressant tianeptine also shows potential for reducing the development of the neurotoxic effects of HIV CNS pathology. Tianeptine protects astrocytic cultures from the pro-apoptotic and neurodegenerative effects of HIV-1 gp120 IIIB through a mechanism that involves the inactivation of NF-κB, suppression of iNOS, and stabilization of cNOS, which final process results in reduced nitric oxide levels (Janda et al. 2011) . Similar findings show the involvement of iNOS and GS pathway as a link between glutamate-mediated insults and the response to inflammatory stimulus by pro-inflammatory cytokines (Muscoli et al. 2005) . In this case the pharmacological inhibition of iNOS during NMDAR stimulation induces neuroprotective properties by favoring glutamate conversion to glutamine through the activity of astroglial GS (Muscoli et al. 2005) and subsequently decreasing glutamate levels in the extracellular space. However, the therapeutic efficacy of tianeptine in ameliorating the severity of HIV-1 neurocognitive decline and improving behavioral and memory deficits in animal models remains to be demonstrated. Lipoic acid constitutes an important cofactor for lipid biosynthesis that has ROS-scavenging capacity. In C6 rat astrocytes, lipoic acid has also been shown to increase GS activity, enhance extracellular glutamate reuptake, and increase endogenous glutathione content and antioxidant capacity (Kleinkauf-Rocha et al. 2013 ) and thus may potentially provide modulatory functions towards glutamate metabolism during CNS HIV-1 infection.
The modulation of signaling pathways, which triggers the induction of glutamate-producing enzymes, such as glutaminase 1 and 2, provides alternative targets for reducing further neurotoxicity. The suppression of glutamate production in HIV-1-infected MDM and microglia can be circumvented by the inhibition of STAT-1 phosphorylation (Zhao et al. 2012) and may represent one of the most important means to reduce the production of extracellular glutamate. In primary neurons from newborn mice, polyphenol epigallocatechin-3-gallate (which is derived from green tea extracts), abolished HIV-1 gp120-or Tat-induced neuronal toxicity by interfering with STAT-1/JAK phosphorylation (Giunta et al. 2006) . In this study, the involvement of STAT-1/JAK signaling was further implicated since neither neurons from STAT-1 knockout mice nor the inhibition of JAK1 responded to IFN-γ-enhanced neurotoxic damage induced by gp120 or Tat (Giunta et al. 2006) . Besides the use of pharmacological strategies aimed at diminishing glutamate production, the enhancement of microglial and astroglial extracellular glutamate clearance is another approach for decreasing worsening of HAND and HIVE. One of the most promising neuromodulatory compounds to use during HIV-1 infection is the antibiotic ceftriaxone. Ceftriaxone is a third generation cephalosporin antibiotic that has neuroprotective effects against glutamate overexcitation by enhancing extracellular glutamate clearance ) and has been used for reestablishing hippocampal function by restoring glutamate homeostasis (Yang et al. 2013) . It has been shown to induce EAAT-2 protein expression in primary human fetal astrocytes by promoting both the nuclear translocation binding of NF-κB to the -282 position of the EAAT-2 promoter and nuclear transcription .
The search for pharmacological compounds may not only have uncovered new mechanisms for understanding the aspects of HIV-related neuropathology that is associated with defects in glutamate metabolism but also have led to the identification of novel ways of modifying and exploiting divergent pathways of its inter-and intracellular neurotransmission. In sum, the focus of future research should be placed on eradicating the neuropathology associated with HAND.
Concluding remarks
HIV-1 infection can lead to neurocognitive impairment and neurodysfunction. Even after cART initiation, neuroinflammation and neurocognitive dysfunction persist in the setting of chronic HIV infection for reasons that are not entirely clear. The purpose of this review was to summarize the underlying mechanisms of the glutamate/glutamine cycle and its role in the development of HIV-1 associated neurocognitive disorders. There are several different mechanisms by which HIV-1 can mediate the development of HAND; however, there are issues that remain unsolved. It will be necessary to determine whether the same mechanisms that operate in in vitro studies operate under physiological conditions during the development of HAND. Alternatively, all proposed mechanisms could operate at the same time, but each contributing a different portion to the total amount of pathologies observed.
In sum, the underlying mechanisms of glutamate-induced neurotoxicity in HAND are complex, as shown by experimental CNS HIV-1 models and as seen in the autopsies of brain specimens (Xing et al. 2009; Zhao et al. 2001) . Glutamate establishes an important link between amino acid and energy metabolism, as defects in these pathways are observed in other neurological diseases. Neuronal and glial glutamate metabolism comprises an important system capable of ameliorating the neurological complications observed in HAND, unless disrupted. In addition, the metabolic compartmentalization of glutamate within cellular organelles serves a number of purposes; it maintains antioxidant balance by increasing glutathione levels (Zhang and Forman 2012) and it acts as an amino acid precursor that is required for protein synthesis. The neurocognitive deficits in HIV-1 subjects are associated with disrupted glutamate levels within the cells of the nervous tissues (Ernst et al. 2010 ) and lower antioxidant defense (Zhao et al. 2001) . Both viral products and inflammatory cytokines trigger the increase in oxidative damage and the impaired glial regulation (or use maintenance) of glutamate as a consequence of improper immune responses. Although neuroinflammation and immunological failure both play decisive roles in HIV-1 CNS disease severity in various ways, glutamate-mediated neuronal apoptosis and glial dysfunction appear to be at the center of neuropathological development. Therefore, future research must more closely scrutinize the modulatory factors of CNS glutamate metabolism and neurotransmission for the development of effective therapies that help ameliorate the neurotoxic burden by the imbalance of CNS glutamate-responsive activities.
